Siemers, Eric

NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease

Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 10,537

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease

Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 7,155

Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup

Jack, C. R., Andrews, J. S., Beach, T. G., Buracchio, T., Dunn, B., Graf, A., Hansson, O., Ho, C., Jagust, W., McDade, E., et al. (2024) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 2,803

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 2,065

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 1,668

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 1,224

Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., Hager, K., Andreasen, N., Scarpini, E., Liu-Seifert, H., et al. (2018) · New England Journal of Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 1,049

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup

Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 857

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients

Siemers, E. R., Sundell, K. L., Carlson, C., Case, M., Sethuraman, G., Liu‐Seifert, H., Dowsett, S. A., Pontecorvo, M. J., Dean, R. A., & Demattos, R. (2016) · Alzheimer's & Dementia

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 370

Practice effects and the use of alternate forms in serial neuropsychological testing

BEGLINGER, L., GAYDOS, B., TANGPHAODANIELS, O., DUFF, K., KAREKEN, D., CRAWFORD, J., FASTENAU, P., & SIEMERS, E. (2005) · Archives of Clinical Neuropsychology

Psychological Testing and AssessmentHistorical and Modern Theater Studies

Cited by 362

Rate of functional decline in Huntington’s disease

Marder, K., Zhao, H., Myers, R. H., Cudkowicz, M., Kayson, E., Kieburtz, K., Orme, C., Paulsen, J., Penney, J. B., Siemers, E., et al. (2000) · Neurology

Genetic Neurodegenerative DiseasesNeurological disorders and treatments

Cited by 362

A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system

Bateman, R. J., Siemers, E. R., Mawuenyega, K. G., Wen, G., Browning, K. R., Sigurdson, W. C., Yarasheski, K. E., Friedrich, S. W., DeMattos, R. B., May, P. C., et al. (2009) · Annals of Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 322

Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force

Vellas, B., Carrillo, M. C., Sampaio, C., Brashear, H. R., Siemers, E., Hampel, H., Schneider, L. S., Weiner, M., Doody, R., Khachaturian, Z., et al. (2013) · Alzheimer's & Dementia

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 147

Identification of genetic risk factors in the Chinese population implicates a role of immune system in Alzheimer’s disease pathogenesis

Zhou, X., Chen, Y., Mok, K. Y., Zhao, Q., Chen, K., Chen, Y., Hardy, J., Li, Y., Fu, A. K. Y., Guo, Q., et al. (2018) · Proceedings of the National Academy of Sciences

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 96

Expectations and clinical meaningfulness of randomized controlled trials

Petersen, R. C., Aisen, P. S., Andrews, J. S., Atri, A., Matthews, B. R., Rentz, D. M., Siemers, E. R., Weber, C. J., & Carrillo, M. C. (2023) · Alzheimer's & Dementia

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 95

A COMBINED MEASURE OF COGNITION AND FUNCTION FOR CLINICAL TRIALS: THE INTEGRATED ALZHEIMER’S DISEASE RATING SCALE (IADRS)

Wessels, A. M., Siemers, E. R., Yu, P., Andersen, S. W., Holdridge, K. C., Sims, J. R., Sundell, K., Stern, Y., Rentz, D. M., Dubois, B., et al. (2015) · The Journal of Prevention of Alzheimer's Disease

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 86

Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial

Feigin, A., Evans, E. E., Fisher, T. L., Leonard, J. E., Smith, E. S., Reader, A., Mishra, V., Manber, R., Walters, K. A., Kowarski, L., et al. (2022) · Nature Medicine

Genetic Neurodegenerative DiseasesParkinson's Disease Mechanisms and Treatments

Cited by 67

Magnetic resonance imaging measures of brain atrophy from the EXPEDITION3 trial in mild Alzheimer's disease

Schwarz, A. J., Sundell, K. L., Charil, A., Case, M. G., Jaeger, R. K., Scott, D., Bracoud, L., Oh, J., Suhy, J., Pontecorvo, M. J., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 40

Cognitive go/No-go decision-making criteria in Alzheimer’s disease drug development

Wessels, A. M., Edgar, C. J., Nathan, P. J., Siemers, E. R., Maruff, P., & Harrison, J. (2021) · Drug Discovery Today

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 7

Evidence that semaphorin 4D is upregulated in neurons in Huntington’s and Alzheimer’s diseases: Effects of a SEMA4D blocking antibody on FDG‐PET in a clinical trial, and treatment rationale for its use in AD: Human/Human trials: Other

Evans, E. E., Fisher, T. L., Leonard, J. E., Reader, A. M., Mishra, V., Mallow, C. L., Balch, L., Howell, A., Smith, E. S., Feigin, A., et al. (2020) · Alzheimer's & Dementia

Alzheimer's disease research and treatmentsGenetic Neurodegenerative Diseases

Cited by 7

E.U./U.S. CTAD TASK FORCE ON ALZHEIMER\'S TRIAL POPULATIONS

Vellas, B., Sampaio, C., Bateman, R., Boxer, A., Carrillo, M. C., Cummings, J., Dubois, B., Hampel, H., Katz, R., Khachaturian, Z., et al. (2014) · The Journal of Prevention of Alzheimer's Disease

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 5